Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
| Autor: | Francesca Belardinilli, Cristina Raimondi, Yasaman Mahdavian, Paola Gazzaniga, Flavia Loreni, Giuseppe Giannini, Angela Gradilone, Enrico Cortesi, Alain Gelibter, Chiara Nicolazzo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Cancer Research Colorectal cancer Mutant Biology medicine.disease_cause Somatic evolution in cancer lcsh:RC254-282 metastatic colorectal cancer circulating tumor DNA RAS EGFR inhibitors 03 medical and health sciences Negative selection 0302 clinical medicine medicine Mutation Communication Wild type medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Primary tumor 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research |
| Zdroj: | Cancers, Vol 11, Iss 1, p 42 (2019) Cancers |
| ISSN: | 2072-6694 |
| Popis: | Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of RAS mutant clones in plasma has been more recently reported in some patients with primary RAS mutant cancers, supporting for the first time an unexpected negative selection of RAS mutations during the clonal evolution of mCRC. To date, the extent of conversion to RAS wild type disease at the time of progression has not been clarified yet. As a proof of concept, we prospectively enrolled mCRC patients progressing under anti-VEGF based treatments. Idylla™ system was used to screen RAS mutations in plasma and the wild type status of RAS was further confirmed through IT-PGM (Ion Torrent Personal Genome Machine) sequencing. RAS was found mutant in 55% of cases, retaining the same plasma mutation as in the primary tumor at diagnosis, while it was found wild-type in 45%. Four patients testing negative for RAS mutations in plasma at the time of progression of disease (PD) were considered eligible for treatment with EGFR inhibitors and treated accordingly, achieving a clinical benefit. We here propose a hypothetical algorithm that accounts for the transient disappearance of RAS mutant clones over time, which might extend the continuum of care of mutant RAS colorectal cancer patients through the delivery of a further line of therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |